NCT05150717View on ClinicalTrials.gov

ADME Study of [14C]-Jaktinib in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

January 30, 2022

Study Completion Date

January 30, 2022

Conditions
Healthy Adult Male Volunteers
Interventions
DRUG

[14C]-Jaktinib

Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.

Trial Locations (1)

Unknown

The First Affiliated Hospital of soochow University, Suzhou

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT05150717 - ADME Study of [14C]-Jaktinib in Healthy Male Subjects | Biotech Hunter | Biotech Hunter